Abstract
Previous investigations in animals and one retrospective study in man suggest that verapamil can prevent anthracycline-induced cardiomyopathy. In the following study, patients with acute myeloid leukemia (AML) treated with double induction and consolidation chemotherapy (AML COOP study 1986, [3]) were randomized in a group with and without accompanying low-dose oral verapamil treatment. Since July 1986, 64 patients have been included. Thirty patients have been evaluated for pre- and posttreatment cardiological investigations. So far, no significant difference in cardiotoxicity has been observed either between the verapamil and nonverapamil group or between the two induction chemotherapy regimens (TAD/TAD - TAD/HAM).
Publication types
-
Clinical Trial
-
Comparative Study
-
Multicenter Study
-
Randomized Controlled Trial
MeSH terms
-
Adolescent
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Cardiomyopathies / chemically induced
-
Cardiomyopathies / drug therapy*
-
Cytarabine / administration & dosage
-
Daunorubicin / administration & dosage
-
Daunorubicin / adverse effects*
-
Hemodynamics / drug effects
-
Humans
-
Leukemia, Myeloid, Acute / complications
-
Leukemia, Myeloid, Acute / drug therapy*
-
Leukemia, Myelomonocytic, Acute / complications
-
Leukemia, Myelomonocytic, Acute / drug therapy*
-
Middle Aged
-
Mitoxantrone / administration & dosage
-
Multicenter Studies as Topic
-
Prospective Studies
-
Randomized Controlled Trials as Topic
-
Thioguanine / administration & dosage
-
Verapamil / pharmacology
-
Verapamil / therapeutic use*
Substances
-
Cytarabine
-
Mitoxantrone
-
Verapamil
-
Thioguanine
-
Daunorubicin
Supplementary concepts
-
DAT protocol 1
-
NOAC protocol